Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript
Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.64, expectations were $-0.76. Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (XENE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 5,666,666 | $261,006,636 | +16% | 3.6% |
| 2. | Driehaus Capital Richard Driehaus | 4,345,180 | $200,138,991 | -4% | 2.41% |
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 3,066,628 | $141,248,886 | +3% | 0.86% |
| 4. | Commodore Capital Egen Atkinson And Michael Kramarz | 2,167,793 | $99,848,546 | +18% | 8.72% |
| 5. | Braidwell LP Alex Karnal | 1,647,311 | $75,875,145 | -22% | 2.78% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.81 | 700 | Officer | 700 | 2022-01-21 | Filing | |
| $24.40 | 4,000 | Officer | 4,000 | 2021-12-06 | Filing | |
| $2.22 | 15,000 | Director | 44,210 | 2017-11-15 | Filing | |
| $2.95 | 8,000 | Director | 29,210 | 2017-09-22 | Filing | |
| $2.95 | 2,000 | Director | 21,210 | 2017-09-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $45.69 | 2,092 | 0 | 2024-03-08 | Filing | ||
| $46.30 | 6,118 | 8,398 | 2024-03-07 | Filing | ||
| $46.15 | 1,019 | 14,516 | 2024-03-07 | Filing | ||
| $46.20 | 2,000 | 2,000 | 2024-03-07 | Filing | ||
| $46.30 | 5,000 | 4,000 | 2024-03-07 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,655,922 | $260,511,767 | 0.02% | |
| 2. | 4,162,654 | $191,731,844 | 0.03% | |
| 3. | 2,681,537 | $123,511,594 | 0.02% | |
| 4. | 2,455,683 | $113,108,759 | 0.02% | |
| 5. | 2,127,400 | $97,988,044 | 4.58% |
News See All
5 Most Promising Stocks to Buy According to Hedge Funds
In this article, we will take a look at the 5 most promising stocks to buy according to hedge funds.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2023 Earnings Call Transcript
Operator: Hello, thank you for standing by. And welcome to Xenon Pharmaceuticals Incorporated Third Quarter 2023 Earnings Conference Call.
13 Best Canadian Stocks to Buy and Hold
The Canadian economy is also facing the heat of inflation and rising interest rates. Analysts are divided when it comes to the probability of recession hitting the country in 2023 or 2024.
5 Best High Risk High Reward Stocks To Buy Now
In this piece, we will take a look at the five best high risk high reward stocks to buy now.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2023 Earnings Call Transcript
Operator: Good afternoon ladies and gentlemen, and thank you for standing by. Welcome to the Xenon Pharmaceuticals Report, Second Quarter 2023 Results Conference Call.
11 Best Healthcare Stocks Under $50
In this article, we will be taking a look at the 11 best healthcare stocks under $50.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2023 Earnings Call Transcript
Operator: Hello, and thank you for standing by. My name is Gigi, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Q1 2023 Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2022 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2022 Xenon Pharmaceuticals, Inc. Earnings Conference Call. I would now like to turn the call over to Sherry Aulin, CFO.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2022 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Q3 2022 Xenon Pharmaceuticals, Inc. Earnings Conference Call.